Skip to main content
Top
Published in: Pituitary 4/2012

01-12-2012

Measurement of oxidative stress and endothelial dysfunction in patients with hypopituitarism and severe deficiency adult growth hormone deficiency

Authors: Daniel González-Duarte, Ainara Madrazo-Atutxa, Alfonso Soto-Moreno, Alfonso Leal-Cerro

Published in: Pituitary | Issue 4/2012

Login to get access

Abstract

Patients with adult GH deficiency (AGHD) have a high cardiovascular risk and probably an alteration of the oxidative balance, although evidence is lacking. To evaluate the presence of endothelial dysfunction and oxidative stress in patients with AGHD. Biochemical parameters of oxidative stress and endothelial dysfunction were compared in 25 patients with previously untreated AGHD and 25 healthy controls matched by age and sex. Multivariate analysis was performed to identify independent predictors of oxidative stress. Vascular function of subcutaneous resistance arteries was also analyzed by means of wire myography in 7 patients with untreated AGHD and in 7 healthy controls with similar characteristics. The values of C-reactive protein, interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-α), were higher in the AGHD group (4.6 vs. 0.2 μg/L, P = 0.02; 5.6 vs. 1.2 pg/mL, P = 0.001; 6.7 vs. 2.1 pg/mL, P = 0.04; respectively). The levels of type-1 vascular cell adhesion molecule, total anti-oxidant state, oxidized LDL (LDL-ox) were also greater in AGHD patients (678 vs. 423 ng/mL, P = 0.004; 1235.6 vs. 1002.3 μmol/L, P = 0.01; 172.2.5 vs. 42.3 ng/mL, P = 0.02; respectively). Nitric oxide (NO), reduced glutathione (GSH) and reduced/oxidized glutathione ratio (GSH/GSSG) values were lower than controls (18.7 vs. 31.6 mmol/mg protein, P = 0.01; 372.2 vs. 756.2 μmol/L, P = 0.03; 17.2 vs. 38.4, P = 0.04; respectively). Multiple regression analysis showed that AGHD was an independent predictor of increased LDL-ox (P = 0.002) and decreased GSH (P = 0.000). Furthermore, the degree of vascular relaxation to repeated exposure of acetylcholine was lower in AGHD (P = 0.025). Patients with AGHD have an increased degree of oxidative stress and endothelial dysfunction that could already be present in early stages of the disease. Studies with a greater number of patients are needed in order to confirm our findings.
Literature
1.
go back to reference Ricart W, Fernandez-Real JM (2003) Impact of hormonal deficit and cardiovascular risk factors on life expectancy in hypopituitarism. Med Clin (Barc) 120(16):630–637CrossRef Ricart W, Fernandez-Real JM (2003) Impact of hormonal deficit and cardiovascular risk factors on life expectancy in hypopituitarism. Med Clin (Barc) 120(16):630–637CrossRef
2.
go back to reference Evans LM, Davies JS, Anderson RA, Ellis GR, Jackson SK, Lewis MJ, Frenneaux MP, Rees A, Scanlon MF (2000) The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol 142(3):254–262PubMedCrossRef Evans LM, Davies JS, Anderson RA, Ellis GR, Jackson SK, Lewis MJ, Frenneaux MP, Rees A, Scanlon MF (2000) The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol 142(3):254–262PubMedCrossRef
3.
go back to reference Colao A, Di Somma C, Savanelli MC, De Leo M, Lombardi G (2006) Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm IGF Res 16(Suppl):S41–S48PubMedCrossRef Colao A, Di Somma C, Savanelli MC, De Leo M, Lombardi G (2006) Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm IGF Res 16(Suppl):S41–S48PubMedCrossRef
4.
go back to reference Bollerslev J, Ueland T, Jorgensen AP, Fougner KJ, Wergeland R, Schreiner T, Burman P (2006) Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol 154(4):537–543PubMedCrossRef Bollerslev J, Ueland T, Jorgensen AP, Fougner KJ, Wergeland R, Schreiner T, Burman P (2006) Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol 154(4):537–543PubMedCrossRef
5.
go back to reference Colao A, Di Somma C, Spiezia S, Savastano S, Rota F, Savanelli MC, Lombardi G (2008) Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab 93(9):3416–3424PubMedCrossRef Colao A, Di Somma C, Spiezia S, Savastano S, Rota F, Savanelli MC, Lombardi G (2008) Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab 93(9):3416–3424PubMedCrossRef
6.
go back to reference Fukuda I, Hizuka N, Ishikawa Y, Itoh E, Yasumoto K, Murakami Y, Sata A, Tsukada J, Kurimoto M, Okubo Y, Takano K (2004) Serum adiponectin levels in adult growth hormone deficiency and acromegaly. Growth Horm IGF Res 14(6):449–454PubMedCrossRef Fukuda I, Hizuka N, Ishikawa Y, Itoh E, Yasumoto K, Murakami Y, Sata A, Tsukada J, Kurimoto M, Okubo Y, Takano K (2004) Serum adiponectin levels in adult growth hormone deficiency and acromegaly. Growth Horm IGF Res 14(6):449–454PubMedCrossRef
7.
go back to reference Gomez JM, Sahun M, Vila R, Domenech P, Catalina P, Soler J, Badimon L (2007) Elevation of Eselectin concentrations may correlate with potential endothelial dysfunction in individuals with hypopituitarism during therapy with growth hormone. Curr Neurovasc Res 4(1):55–62PubMedCrossRef Gomez JM, Sahun M, Vila R, Domenech P, Catalina P, Soler J, Badimon L (2007) Elevation of Eselectin concentrations may correlate with potential endothelial dysfunction in individuals with hypopituitarism during therapy with growth hormone. Curr Neurovasc Res 4(1):55–62PubMedCrossRef
8.
go back to reference Joaquin C, Aguilera E, Granada ML, Pastor MC, Salinas I, Alonso N, Sanmarti A (2008) Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur J Endocrinol 158(4):483–490PubMedCrossRef Joaquin C, Aguilera E, Granada ML, Pastor MC, Salinas I, Alonso N, Sanmarti A (2008) Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur J Endocrinol 158(4):483–490PubMedCrossRef
9.
go back to reference Osterziel KJ, Bode-Boger SM, Strohm O, Ellmer AE, Bit-Avragim N, Hanlein D, Ranke MB, Dietz R, Boger RH (2000) Role of nitric oxide in the vasodilator effect of recombinant human growth hormone in patients with dilated cardiomyopathy. Cardiovasc Res 45(2):447–453PubMedCrossRef Osterziel KJ, Bode-Boger SM, Strohm O, Ellmer AE, Bit-Avragim N, Hanlein D, Ranke MB, Dietz R, Boger RH (2000) Role of nitric oxide in the vasodilator effect of recombinant human growth hormone in patients with dilated cardiomyopathy. Cardiovasc Res 45(2):447–453PubMedCrossRef
10.
go back to reference Setola E, Monti LD, Lanzi R, Lucotti P, Losa M, Gatti E, Galluccio E, Oldani M, Fermo I, Giovannelli M, Bosi E, Piatti P (2008) Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency. Metabolism 57(12):1685–1690PubMedCrossRef Setola E, Monti LD, Lanzi R, Lucotti P, Losa M, Gatti E, Galluccio E, Oldani M, Fermo I, Giovannelli M, Bosi E, Piatti P (2008) Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency. Metabolism 57(12):1685–1690PubMedCrossRef
11.
go back to reference Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN (1999) Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 84(2):453–457PubMedCrossRef Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN (1999) Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 84(2):453–457PubMedCrossRef
12.
go back to reference McCallum RW, Sainsbury CA, Spiers A, Dominiczak AF, Petrie JR, Sattar N, Connell JM (2005) Growth hormone replacement reduces C-reactive protein and large-artery stiffness but does not alter endothelial function in patients with adult growth hormone deficiency. Clin Endocrinol (Oxf) 62(4):473–479CrossRef McCallum RW, Sainsbury CA, Spiers A, Dominiczak AF, Petrie JR, Sattar N, Connell JM (2005) Growth hormone replacement reduces C-reactive protein and large-artery stiffness but does not alter endothelial function in patients with adult growth hormone deficiency. Clin Endocrinol (Oxf) 62(4):473–479CrossRef
13.
go back to reference Paisley AN, Izzard AS, Gemmell I, Cruickshank K, Trainer PJ, Heagerty AM (2009) Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly. J Clin Endocrinol Metab 94(4):1111–1117PubMedCrossRef Paisley AN, Izzard AS, Gemmell I, Cruickshank K, Trainer PJ, Heagerty AM (2009) Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly. J Clin Endocrinol Metab 94(4):1111–1117PubMedCrossRef
14.
go back to reference Colao A, Di Somma C, Cuocolo A, Filippella M, Rota F, Acampa W, Savastano S, Salvatore M, Lombardi G (2004) The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study. J Clin Endocrinol Metab 89(12):5998–6004PubMedCrossRef Colao A, Di Somma C, Cuocolo A, Filippella M, Rota F, Acampa W, Savastano S, Salvatore M, Lombardi G (2004) The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study. J Clin Endocrinol Metab 89(12):5998–6004PubMedCrossRef
15.
go back to reference Colao A, Cerbone G, Pivonello R, Aimaretti G, Loche S, Di Somma C, Faggiano A, Corneli G, Ghigo E, Lombardi G (1999) The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. J Clin Endocrinol Metab 84(4):1277–1282PubMedCrossRef Colao A, Cerbone G, Pivonello R, Aimaretti G, Loche S, Di Somma C, Faggiano A, Corneli G, Ghigo E, Lombardi G (1999) The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. J Clin Endocrinol Metab 84(4):1277–1282PubMedCrossRef
16.
go back to reference Menezes Oliveira JL, Marques-Santos C, Barreto-Filho JA, Ximenes Filho R, de Oliveira Britto AV, Oliveira Souza AH, Prado CM, Pereira Oliveira CR, Pereira RM, Ribeiro Vicente Tde A, Farias CT, Aguiar-Oliveira MH, Salvatori R (2006) Lack of evidence of premature atherosclerosis in untreated severe isolated growth hormone (GH) deficiency due to a GH-releasing hormone receptor mutation. J Clin Endocrinol Metab 91(6):2093–2099PubMedCrossRef Menezes Oliveira JL, Marques-Santos C, Barreto-Filho JA, Ximenes Filho R, de Oliveira Britto AV, Oliveira Souza AH, Prado CM, Pereira Oliveira CR, Pereira RM, Ribeiro Vicente Tde A, Farias CT, Aguiar-Oliveira MH, Salvatori R (2006) Lack of evidence of premature atherosclerosis in untreated severe isolated growth hormone (GH) deficiency due to a GH-releasing hormone receptor mutation. J Clin Endocrinol Metab 91(6):2093–2099PubMedCrossRef
17.
go back to reference Ozbey N, Telci A, Cakatay U, Yurci A, Molvalilar S (2003) Determination of oxidative protein and lipid damage in adult hypopituitary patients with GH deficiency. J Endocrinol Invest 26(10):1001–1007PubMed Ozbey N, Telci A, Cakatay U, Yurci A, Molvalilar S (2003) Determination of oxidative protein and lipid damage in adult hypopituitary patients with GH deficiency. J Endocrinol Invest 26(10):1001–1007PubMed
18.
go back to reference Skalicky J, Muzakova V, Kandar R, Meloun M, Rousar T, Palicka V (2008) Evaluation of oxidative stress and inflammation in obese adults with metabolic syndrome. Clin Chem Lab Med 46(4):499–505PubMedCrossRef Skalicky J, Muzakova V, Kandar R, Meloun M, Rousar T, Palicka V (2008) Evaluation of oxidative stress and inflammation in obese adults with metabolic syndrome. Clin Chem Lab Med 46(4):499–505PubMedCrossRef
19.
go back to reference Rossi R, Dalle-Donne I, Milzani A, Giustarini D (2006) Oxidized forms of glutathione in peripheral blood as biomarkers of oxidative stress. Clin Chem 52(7):1406–1414PubMedCrossRef Rossi R, Dalle-Donne I, Milzani A, Giustarini D (2006) Oxidized forms of glutathione in peripheral blood as biomarkers of oxidative stress. Clin Chem 52(7):1406–1414PubMedCrossRef
20.
go back to reference Smith JC, Lang D, McEneny J, Evans LM, Scanlon MF, Young I, Davies J (2002) Effects of GH on lipid peroxidation and neutrophil superoxide anion-generating capacity in hypopituitary adults with GH deficiency. Clin Endocrinol (Oxf) 56(4):449–455CrossRef Smith JC, Lang D, McEneny J, Evans LM, Scanlon MF, Young I, Davies J (2002) Effects of GH on lipid peroxidation and neutrophil superoxide anion-generating capacity in hypopituitary adults with GH deficiency. Clin Endocrinol (Oxf) 56(4):449–455CrossRef
21.
go back to reference Scacchi M, Valassi E, Pincelli AI, Fatti LM, Pecori Giraldi F, Ascoli P, Viarengo R, Cestaro B, Cavagnini F, Cazzola R (2006) Increased lipid peroxidation in adult GH-deficient patients: effects of short-term GH administration. J Endocrinol Invest 29(10):899–904PubMed Scacchi M, Valassi E, Pincelli AI, Fatti LM, Pecori Giraldi F, Ascoli P, Viarengo R, Cestaro B, Cavagnini F, Cazzola R (2006) Increased lipid peroxidation in adult GH-deficient patients: effects of short-term GH administration. J Endocrinol Invest 29(10):899–904PubMed
23.
go back to reference Buus NH, Simonsen U, Pilegaard HK, Mulvany MJ (2000) Nitric oxide, prostanoid and non-NO, non-prostanoid involvement in acetylcholine relaxation of isolated human small arteries. Br J Pharmacol 129(1):184–192PubMedCrossRef Buus NH, Simonsen U, Pilegaard HK, Mulvany MJ (2000) Nitric oxide, prostanoid and non-NO, non-prostanoid involvement in acetylcholine relaxation of isolated human small arteries. Br J Pharmacol 129(1):184–192PubMedCrossRef
Metadata
Title
Measurement of oxidative stress and endothelial dysfunction in patients with hypopituitarism and severe deficiency adult growth hormone deficiency
Authors
Daniel González-Duarte
Ainara Madrazo-Atutxa
Alfonso Soto-Moreno
Alfonso Leal-Cerro
Publication date
01-12-2012
Publisher
Springer US
Published in
Pituitary / Issue 4/2012
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-011-0374-4

Other articles of this Issue 4/2012

Pituitary 4/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.